July 6, 2016 KIACTA for the treatment of AA amyloidosis - Clinical Phase 3 trial top line results - Presentation at the International Symposium on Amyloidosis on July 6, 2016

Stock Quote



Price $ 0.28

Change +0.01 (+1.82%)

Volume 55,020

Day High $ 0.29

Day Low $ 0.28

52 Week High $ 2.99


52 Week Low $ 0.21

Today's Open $ 0.29

Previous Close $ 0.28

Mar 23, 2017 01:36 PM Pricing delayed 20 minutes

Financials & Filings

View All


April 8, 2016 CEO Message to Shareholders (from 2015 Annual Report)
Dear Shareholders, We have made important progress in our business plan in 2015 that has setup the coming year to be one of the most important in our Company history. Developing Rare Disease Drugs is a Growing Trend Regulatory agencies, and particularly the US Food and Drug Administration (FDA), are increasingly approving innovative drugs and in particular drugs that treat rare diseases. Last...
Read More
December 1, 2015 The Perils Of A Big Pharma Partnership
– What a Megamerger Like Pfizer and Allergan’s Can Mean to Biotech Partnerships – The media commentary around Pfizer and Allergan’s mega merger announced earlier this week has focused primarily around the fact that the deal is structured as a corporate inversion so that Pfizer can reduce its expected tax rate from 25% to 17%. While investors are sweating over whether the US government will...
Read More

Share this

Sign up for email alerts

Email Address *
Enter the code shown above.